No Detail Found!

Elucidating Astragaloside IV's Anti-Glioma Action via Network Pharmacology, Molecular Docking, and Experimental Evidence for PI3K/AKT Pathway Inhibition

Author(s)
Ting Wang Laboratory of clinical medicine, affiliated hospital of Gansu University of Chinese Medicine,Lanzhou, 730000,People's Republic of China
Jing Han Department of Research Management, Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Lanzhou 730000, People's Republic of China
Rong Su Gansu Key Laboratory of Pharmacology and Toxicology of Traditional Chinese Medicine, Gansu Research Center of Traditional Chinese Medicine, Lanzhou 730000, People's Republic of China
Zhuanxiong Wang Gansu Key Laboratory of Pharmacology and Toxicology of Traditional Chinese Medicine, Gansu Research Center of Traditional Chinese Medicine, Lanzhou 730000, People's Republic of China
Shuping Qiu Gansu Key Laboratory of Pharmacology and Toxicology of Traditional Chinese Medicine, Gansu Research Center of Traditional Chinese Medicine, Lanzhou 730000, People's Republic of China
Zhe Jing Gansu Key Laboratory of Pharmacology and Toxicology of Traditional Chinese Medicine, Gansu Research Center of Traditional Chinese Medicine, Lanzhou 730000, People's Republic of China
Xiaoqiang Gao Health Examination Center, Affiliated Dingxi Hospital of Changchun University of Traditional Chinese Medicine, Dingxi 743000, People's Republic of China
Hailong Li Department of Research Management, Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Lanzhou 730000, People's Republic of China; Gansu Key Laboratory of Pharmacology and Toxicology of Traditional Chinese Medicine, Gansu Research Center of Traditional Chinese Medicine, Lanzhou 730000, People's Republic of China
Abstract
Objective: To investigate astragaloside IV's (AS-IV) anti-glioma effects and mechanisms. Methods: Potential ASIV targets were screened using SwissTarget, Super PRED, and PharmMapper databases. Glioma-related targets were identified from GeneCards, OMIM, and TTD. Intersection genes underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Anti-glioma mechanisms were investigated using A172 and U251 glioma cell lines. Cells were treated with AS-IV at 20, 30, or 50 mg/mL. MTT assessed proliferation. Cell scratch and transwell assays evaluated invasion. Flow cytometry analyzed cell cycle distribution and apoptosis. Western blot measured expression of cell cycle, apoptosis, epithelial-mesenchymal transition, and PI3K-AKT pathway-related genes. Results: Network pharmacology and molecular docking predicted AS-IV anti-glioma targets were associated with the PI3K/AKT pathway. AS-IV inhibited A172 and U251 cell proliferation and invasion dose- and time-dependently. It arrested the cell cycle in G0/G1 phase and induced apoptosis. AS-IV upregulated P21, Bax, and E-cadherin expression while downregulating CDK4, CDK6, Bcl-2, Vimentin, PPI3K, and P-AKT. Conclusion: AS-IV exhibits anti-tumor effects against glioma cells, potentially by inhibiting the PI3K/AKT signaling pathway. This leads to apoptosis induction, proliferation suppression, cell cycle arrest, and invasion inhibition.
Publication Details
Page(s) 23-33
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: 9, Year: 2025

Request the full text from PASTIC

Keywords
Glioma, molecular docking, Astragaloside IV, PI3K/AKT Pathway
References
Auyeung K.K. .2016 ."Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers.". American Journal of Chinese Medicine, 10 : 1-22.
Chen R. .2017 ."Glioma subclassifications and their clinical significance. " Neurotherapeutics, 10 : 284-297.
Faustino A.C. .2020 ."Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide." Clinics (São Paulo). , 10 : .
Wu W. .2021 ."Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance.". Pharmacological Research, 10 : .
Ou A. .2020 ."Molecular mechanisms of treatment resistance in glioblastoma.". International Journal of Molecular Sciences, 10 : .
Zhang J. .2019 ."Astragaloside IV derived from Astragalus membranaceus: a research review on the pharmacological effects." Advances in Pharmacology. , 08 : 89-112.
Li Z. .2022 ."Research progress of Astragalus membranaceus in treating peritoneal metastatic cancer. " Journal of Ethnopharmacology, 116086 : .
Feng Y. .2023 ."A network pharmacology prediction and molecular docking-based strategy to explore the potential pharmacological mechanism of Astragalus membranaceus for glioma.". International Journal of Molecular Sciences, 10 : .
Sheng F. .2024 ."Research progress on the anti-cancer effects of Astragalus membranaceus saponins and their mechanisms of action.". Molecules, 10 : .
Liu Y. .2023 ."Anticancer effect of active component of Astragalus membranaceus combined with olaparib on ovarian cancer predicted by network-based pharmacology. " Applied Biochemistry and Biotechnology, 10 : 6994-7020.
Huang P. .1885 ."Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness.". Translational Cancer Research, 10 : 3703-3717.
Zhu S. .2024 ."Integrating network pharmacology and experimental verification to explore the pharmacological mechanisms of Radix Paeoniae Rubra against glioma. " Applied Biochemistry and Biotechnology, 10 : .
Li S. .2024 ."Network pharmacology-based investigation of the effects of Shenqi Fuzheng injection on glioma proliferation and migration via the SRC/PI3K/AKT signaling pathway. " Journal of Ethnopharmacology, 118128 : .
Liu Y. .2022 ."CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. " Nucleic Acids Research, 10 : W159-W164.
Majc B. .2020 ."Epithelial-to-mesenchymal transition as the driver of changing carcinoma and glioblastoma microenvironment.". Biochimica et Biophysica Acta - Molecular Cell Research, 118782 : .
Wu Y. .2020 ."Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway. " International Immunopharmacology, 107290 : .
Yu J. .2019 ."Astragaloside IV protects neurons from microglia-mediated cell damage through promoting microglia polarization. " Folia Neuropathologica, 86299 : 170-181.
Liu B. .2020 ."Astragaloside IV attenuates lipopolysaccharidesinduced pulmonary epithelial cell injury through inhibiting autophagy. " Pharmacology, 10 : 90-101.
Li M. .2016 ."Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. " Neuroscience Letters, 12 : 114-119.
Wang X. .2020 ."Astragaloside IV antagonizes M2 phenotype macrophage polarization-evoked ovarian cancer cell malignant progression by suppressing the HMGB1-TLR4 axis.". Molecular Immunology, 11 : 113-121.
Wiese W. .2023 ."PI3K/Akt/mTOR signaling pathway in blood malignancies - new therapeutic possibilities." Cancers (Basel). , 10 : .
Maharati A.,Moghbeli M. .2023 ."PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells." Cell Communication and Signaling. , 10 : .
Iz ,Swieszewska E. .2010 ."Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours.". -CR.1., 10 : 09-198.
Glaviano A. .2023 ."PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. " Molecular Cancer, 10 : .
Noronha C. .2021 ."Cadherin expression and EMT: a focus on gliomas. " Biomedicines, 10 : .
Wu H. .2024 ."The clinical significance of SNAIL, TWIST, and E-cadherin expression in gastric mesentery tumor deposits of advanced gastric cancer.". Indian Journal of Pathology and Microbiology, 659 : 22-28.
Coelho-Rato L.S. .2023 ."Vimentin at the core of wound healing." Trends in Cell Biology. , 08 : 239-254.
Satelli A.,Li S. .2011 ."Vimentin in cancer and its potential as a molecular target for cancer therapy. " Cellular and Molecular Life Sciences, 10 : 3033-3046.
Fassl A. .2022 ."CDK4 and CDK6 kinases: from basic science to cancer therapy.". Science, 10 : .
Zhou L. .2022 ."Anticancer effects and mechanisms of astragaloside-IV (review. " Oncology Reports, 8442 : .
0

Citations

0

Downloads

44

Views